Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Jazz Pharmaceuticals

Pfizer

Biotech investing is not for impatient investors. So why is it attractive to some investors?

3 Biotech Stocks to Buy on the Dip: February 2024

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30 a.m. ET in New York.

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

An analyst upgraded his recommendation on the biotech. He thinks it stands in front of an excellent opportunity in the treatment of an inherited disorder.

Why Beam Therapeutics Stock Zoomed 17% Higher Today

Arcellx

Regeneron Pharmaceuticals

Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.

Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market

Edgewise Therapeutics

Monte Rosa Therapeutics

Pre-revenue innovation companies have been in a two-year slump thanks to rising interest rates. With the Federal Reserve poised to start cutting rates later this year, this equity group could be gearing up for a rally.

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Editas Medicine

Verve Therapeutics

The promise of gene editing is moving closer to being a reality. If you're an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene editing stocks.

3 Stocks to Buy in the Booming Field of Gene Editing

First Patient Dosed and Successfully Engrafted in BEACON Phase 1/2 Trial of BEAM-101 in Patients with Severe Sickle Cell Disease; Significant Enrollment Progress Supports First Expected Clinical Data Readout in Second Half of 2024 European Clinical Trial Application (CTA) Submitted for BEAM-302; Trial Initiation in Alpha-1 Antitrypsin Deficiency Planned for First Half of 2024 Investigational New Drug (IND) Application for BEAM-301 On-track for First Half of 2024 Cash Runway Expected to Support Operating Plans into 2027 CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company's hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones.

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Ginkgo Bioworks Holdings

Guardant Health Inc

Intellia Therapeutics

Guardant Health has tremendous opportunities in early cancer detection and cancer therapy selection. Beam Therapeutics and Intellia Therapeutics are pioneers in gene editing.

4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

Archer Aviation

Cerus

Invitae

Cathie Wood's ARK Innovation ETF isn't afraid to go against Wall Street and the S&P 500. But in some cases, the consensus agrees with the famed ETF manager.

Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024

BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.

BEAM Stock Rallies More Than 25% in 3 Months: What Next?

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 11:15 a.m. PT in San Francisco.

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

908 Devices

Cathie Wood's Ark Invest has been at the center of the thematic investing revolution. Two of Wood's healthcare picks, 908 Devices and Beam Therapeutics, have garnered lofty price targets from analysts.

2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors.

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

3 Biotechs With Promising Gene Therapies in the Spotlight

Beam Therapeutics Inc. (BEAM) reported earnings 30 days ago. What's next for the stock?

Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?

ARK Genomic Revolution Multi-Sector ETF

Caribou Biosciences

CRISPR Therapeutics

Robinhood

Eli Lilly

Prime Medicine Inc

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

The mean of analysts' price targets for Beam Therapeutics Inc. (BEAM) points to an 81.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade

Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide range of point mutations, making it applicable to many genetic disorders. Beam Therapeutics has several investigational therapies in its pipeline, including treatments for sickle cell disease, T-cell acute lymphoblastic leukemia, and glycogen storage disease 1a.

CRISPR Gene Editing: Beam Therapeutics

Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics (NASDAQ: CRSP ), a move that could set off a firestorm of interest in all things gene editing.

The 3 Best Gene Editing Stocks on the Frontier of Medicine

Beam Therapeutics has what it needs to try to deliver its next clinical milestones. It's still running years behind other biotechs with its lead program.

Is Beam Therapeutics Stock a Buy Now?

Beam Therapeutics Inc. (BEAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock

Twilio

Twilio could be poised to use AI to disrupt customer communications. Beam Therapeutics is a pioneer in developing therapies using a highly precise method of gene editing.

Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks

Beam Therapeutics Inc.'s valuation has declined, as its progress in identifying candidates to work with its base editing technology and moving them into the clinic has been slow. Beam's lead program for Sickle Cell Disease is way behind CRISPR Therapeutics, which may achieve a historic first approval for an ex-vivo cell therapy in December. Beam has sold its stake in Verve Therapeutics' in-vivo candidates to Eli Lilly, potentially missing out on promising development / revenues opportunities.

Beam Therapeutics: Sale Of Rights To Verve's In-Vivo Candidates An Odd Decision

The average of price targets set by Wall Street analysts indicates a potential upside of 139.8% in Beam Therapeutics Inc. (BEAM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect?

Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.

Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates

News for Beam Therapeutics Stock (BEAM)